The Research Center Pharmaceutical Engineering (RCPE) and InSilicoTrials have expanded their partnership to accelerate the development of pharmaceutical manufacturing processes by leveraging high-performance modeling and simulation.
 
The approach enables organizations to innovate and optimize their process configurations without additional investments in technical infrastructure and significantly accelerates time-to-value when developing new drug products. RCPE’s proprietary simulation will be offered as a standalone desktop application and integrated into InSilicoTrials’ market-leading cloud-based platform.
 
“We’re honored to have found the perfect partner in InSilicoTrial,” said Prof. Dr. Johannes Khinast, scientific director of RCPE. “With today‘s announcement, RCPE and InSilicoTrials are combining their expertise to help engineers and researchers make data-driven decisions and deliver new levels of innovation. InSilicoTrials‘ comprehensive simulation platform combined with XPS creates a single-source repository for pharmaceutical development from discovery to dosage form.”
 
“We are honored to have started this collaboration agreement with such a high-value technologically advanced partner,” said Luca Emili, CEO of InSilicoTrials. “This step confirms the validity of our business model centered on the integration of computational simulations from the best research centers worldwide. With XPS, InSilicoTrials adds an important model to its platform, further enhancing its contribution to drug development and data-driven decision making.”
 
Dr. Thomas Klein, business director of RCPE, added, “It is exciting to see our technology ready for commercialization and be able to provide the software to customers worldwide. Our multidisciplinary team has demonstrated how our computational models can be used to create better quality products and more efficient processes. This collaboration and our shared developmental efforts truly set the gold standard for modeling and simulation in life sciences.“